Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here are my top 10 reasons for owning and adding to my SOTK position:
1. SOTK has generated net income for 21 consecutive quarters.
2. SOTK reported record revenues in its latest quarter and EPS of .02.
3. SOTK generates positive cash flow.
4. SOTK has no debt and one of the strong balance sheets you will find on the OTCBB.
5. SOTK has a Fortune 1000 client base.
6. SOTK used to be solely dependent on the electronics industry but has successfully diversified its product line into medical devices, food, textiles, glass and nanotechnology applications.
7. Nanotechnology is projected to become one of the fastest growing industries following in the footsteps of the growth of computing, biotechnology and the Internet.
8. SOTK has successfully expanded its markets into China, India and Eastern Europe, all projected to be fast-growing markets in your lifetime.
9. The management team is strong with the CEO having a senior executive position with GE. In addition management has begun to seek a higher investment community profile with interview at the New York State Investors Conference and with other financial websites.
10. SOTK has only 14 million shares outstanding giving it a tiny market cap of less than $20 million. SOTK is trading near its 52 week low due to tax-loss selling which makes the stock a very strong buy for significant upside potential.
Alert Triggered for MFIC Corp
MFIC Reached a New 52 Week High at $1.88
MFIC rose 2.2% to a new 52 week high of $1.88. During the last 52 weeks, MFIC's price has ranged from $1.10 on August 10, 2006 to today's high of $1.88.
MFIC Engages Kawski Investor Relations to Assist in Investor Relations and Financial Outreach
Thursday December 7, 6:19 pm ET
NEWTON, Mass.--(BUSINESS WIRE)--MFIC Corporation (OTCBB: MFIC - News) today announced that it has engaged Kawski Investor Relations, Inc. for investor outreach, financial communications and strategic investor relations counsel.
"Jim Kawski's investor relations and corporate development experience in high tech capital equipment will add depth and experience to our corporate communications efforts and will assist the Company to effectively communicate with investors and shareholders," said Irwin Gruverman, the Company's Chairman and Chief Executive Officer. "Jim Kawski's broad experience and perspective should help us to effectively get out our targeted message and to communicate our improving positions and prospects," he added.
"MFIC's operating subsidiary, Microfluidics Corporation, is a world leader in high performance processing equipment and a leading early enabler of nanotechnology product manufacture. Its proprietary Microfluidizer® processor systems provide solutions for many industries and applications, including enabling of numerous nanostructured products and nanomaterials," said Mr. Kawski. "MFIC's Fortune 1000 customer list and market penetration in the biopharmaceutical market is most impressive. MFIC has in the last few years executed a turn around and has strengthened its resources and capabilities through a multi-year strategic reinvestment program. MFIC's efforts have resulted in a number of equipment enhancements, improvements and line extensions. To date in 2006 MFIC has attained significant top line growth while maintaining its sound profit margins and improving its balance sheet. MFIC employs enabling technology in its equipment that, in turn, makes possible for its customers to manufacture highly differentiated products and advanced materials and to enhance existing products," he added. "Further, MFIC's developmental continuous chemical reactor technology embodied in its novel Microfluidizer® Mixer/Reactor system (MMR) should provide manufacturers with a highly effective, cost and energy efficient method for performing fast chemical reactions on a nanoscale and for manufacture of high value added nanomaterials and nano-pharmaceuticals."
MFIC CORPORATION
MFIC Corporation, through its Microfluidics subsidiary, provides patented and proprietary high performance Microfluidizer® materials processing equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid structures available, and has provided manufacturing systems for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers. For more information please visit http://www.microfluidicscorp.com/.
Kawski Investor Relations, Inc.
Kawski Investor Relations, Inc. is a consulting firm providing investor relations, and corporate communications services to private and publicly-held companies. Formed in 2006, Kawski Investor Relations focuses on high technology companies in need of science and engineering-based communications counsel and investor outreach. Some of Kawski Investor Relations, Inc.'s current clients include: Entegris, Inc. and Stonehenge Research, LLC. Mr. Kawski is a seasoned investor relations professional with experience in public and private markets. Prior to forming Kawski Investor Relations, Mr. Kawski served most recently as Director of Investor Relations and Corporate Development at Axcelis Technologies, a leader in the manufacture of semiconductor processing equipment. For more information please contact Kawski directly at jkawski@comcast.net.
Contact:
MFIC Corporation
Irwin Gruverman, CEO & Chairman
Jack M. Swig, Investor Relations
617-969-5452
info@mfic.com
www.mficcorp.com
or
Kawski Investor Relations, Inc.
James L. Kawski, 978-490-6827
jkawski@comcast.net
--------------------------------------------------------------------------------
Source: MFIC Corporation
Nanotechnology: The Story Behind the Headlines
PR Newswire - December 07, 2006 11:21
WASHINGTON, Dec 07, 2006 /PRNewswire via COMTEX/ -- Little science is big news, or is it? Does the media tend to hype nanotechnology, or neglect it? Do newspaper headlines focus more on nanotechnology's risks than its benefits? How do journalists write stories on a technology about which most Americans know next to nothing and that is invisible to the human eye?
With governments, corporations and venture capitalists spending $9.6 billion annually on nanotechnology research and development, and with an estimated $2.6 trillion in global manufactured goods incorporating nanotechnology -- or about 15% of total output -- expected by 2014, there is a lot at stake in how these questions are answered.
The Woodrow Wilson Center's Project on Emerging Nanotechnologies will explore these questions at a program featuring The Washington Post's science and medical reporter Rick Weiss, and Leigh University professor Sharon M. Friedman. Mr. Weiss will talk about the challenges of writing about nanotechnology, especially in the face of scant popular understanding of the technology or its potential to change virtually every aspect of people's lives. Professor Friedman will report her findings from six years of tracking U.S. and U.K. newspaper and wire service coverage of nanotechnology risks, work she did in collaboration with Brenda P. Egolf of Lehigh University.
The event and live webcast will take place on Wednesday, December 13th at 10:00 a.m. in the 5th Floor Conference Room of the Woodrow Wilson Center (http://www.wilsoncenter.org/directions).
*** Webcast LIVE at http://www.wilsoncenter.org/nano ***
What: Nanotechnology: The Story Behind the Headlines
Who: Rick Weiss, Medical and Science Reporter, The Washington Post
Sharon M. Friedman, Professor and Director of the Science &
Environmental Writing Program, and Associate Dean, Lehigh
University
David Rejeski, Director, Project on Emerging Nanotechnologies
When: Wednesday, December 13th, 2006, 10:00 - 11:00 a.m.
Where: Woodrow Wilson International Center for Scholars, 5th Floor
Conference Room. 1300 Pennsylvania Avenue, NW, Washington, DC
The Project on Emerging Nanotechnologies was launched in 2005 by the Wilson Center and The Pew Charitable Trusts. It is dedicated to helping business, governments, and the public anticipate and manage the possible health and environmental implications of nanotechnology.
Media planning to cover the event should contact Sharon McCarter at (202) 691-4016 or sharon.mccarter@wilsoncenter.org.
SOURCE Woodrow Wilson International Center for Scholars
Sharon McCarter, Director of Outreach and Communications of Woodrow Wilson
International Center for Scholars, +1-202-691-4016, or
Sharon.mccarter@wilsoncenter.org
http://www.wilsoncenter.org/
Copyright (C) 2006 PR Newswire. All rights reserved
How close are SOTK and MFIC holders to a substantial stock price upmove?
Take a look at a couple of other "picks and shovels" nanotech capital equipment companies that have had big runs recently, LMRA and CVV. The missing ingredient (no pun intended) for MFIC and SOTK at the moment is investor-captivating news.
LMRA has no current fundamentals and a market cap north of $100 Million yet the stock was a quick 7-folder on a couple of positive announcements regarding new product developments and university collaborations.
CVV, which has outstanding fundamentals and a market cap just slightly greater than MFIC and SOTK, provided favorable news about orders and a university collaboration and proceeded to triple in a heart-beat.
I hope MFIC's and SOTK's IR are listening as their solid fundamentals are in place.
MFIC at 1.79 x 1.80 looks coiled like a spring ready to break out to a new 52 week high on any favorable news. Continue to favor the profitable nanotech microcaps, CVV, NVEC, MFIC and SOTK.
CVV has been on a tear this week following its Los Alamos NL contract in the late summer, .07 EPS in the latest quarter vs. .01 last year and latest announcement by the Univ. of Cincinnati that CVV's equipment was used to make the longest carbon nanotube array in history. Applications are military, space, medical, transportation, construction, etc. Thin stock with only 3.2 Million shares out and 1.7 Million in the float.
SOTK's trade show calendar updated:
See us at these trade shows:
Show Location Booth Date
YYYY-MM-DD
--------------------------------------------------------------------------------
Medical Design & Manufacturing Los Angeles, CA Booth # 1341 2007-02-12 To 2007-02-15
Apex/Printed Circuits Expo Los Angeles, CA Booth #2758 2007-02-20 To 2007-02-22
Medtec Exhibition & Conference Stuttgart, Germany Booth # 724 2007-02-27 To 2007-03-01
If I had more time, I would keep up more with nanotech stocks on the thread an post about them. Shmoopy does a great job!
NSLT hot today:
CVV News:
University of Cincinnati Researchers Grow Their Longest Carbon Nanotube Ever
NetComposites.com
Publication Date: December 3, 2006
In conjunction with First Nano (FN), a division of CVD Equipment Corporation, University of Cincinnati Researchers have grown an array on FN’s EasyTube Carbon Nanotube system that is longer than 7 mm.
“The harmonious combination of substrate, alloy catalyst and process conditions was found to consistently produce nanotube arrays more than 7 mm long” says Professor Vesselin Shanov, co-director of Smart Materials Nanotechnology Laboratory at the University of Cincinnati (UC). In recognition for its commitment to nanotechnology education at both the graduate and undergraduate level, UC is ranked #2 in the United States for nanotechnology education by Small Times magazine. “First Nano and UC have collaborated in the past and are planning on future collaboration to scale up production of nanotube arrays for applications that man has only dreamed of, like a super-strong cable for a space elevator and featherweight composite materials for sporting goods, aircraft structures, armour and many more uses.”
The recent breakthroughs at the University of Cincinnati and CVD Equipment Corporation (of Ronkonkoma, New York), have led to the growth of large carbon nanotube arrays. While individual carbon nanotubes are only 20 billionths of a metre in diameter, the array of carbon nanotubes grow as millimetre-long dense forests on centimetre-wide substrates. Years of research by UC’s Shanov, Schulz and students Andrew Gorton and Yun YeoHeung led to the invention of the method for growing the large nanotube arrays. Researchers and engineers at CVD Equipment Corporation developed and built the equipment used to grow the large carbon nanotube arrays.
what a great run
CVV spiked up to above 7 in March '05 after reporting a blowout quarter! But that was before they got into the carbon nanotube business. So we are flirting with an all time high, but with a new perspective about the future.
CVV chart - wow is right!
CVV explosion continues!
NNPP continuation
Nanotech Venture Capital to Exceed $650 Million in 2006
December 04, 2006 04:54 PM Eastern Time
Lux Research Report Finds That out of 171 Venture-Backed Nanotech Start-Ups Funded since 1995, 18 Have Reached a Successful Exit Through an IPO or Acquisition as Money Continues to Flow to the Sector
NEW YORK--(BUSINESS WIRE)--Venture capitalists continue to devote cash to nanotechnology start-up companies. But, with the long expected time from investment to exit of six years – twice what VCs expect for investments in other technology areas – exits are thin on the ground. Nevertheless, some investors are unwisely looking to the small number of exits to date for valuation multiples going forward, according to a new report from Lux Research entitled “Exits for Venture Capitalists in Nanotechnology Remain Elusive.”
“Broadly accepted valuation multiples for companies employing nanotechnology simply don’t exist today because acquisitions and initial public offerings (IPOs) for nanotech start-ups are just beginning to accelerate,” said Lux Research Analyst Ted Sullivan. “It’s tempting to look at today’s few early valuation multiples as benchmarks. We think this will lead to bad decisions – the gestation time for nanotech start-ups is double what venture capitalists expect in other technology areas, making the vast majority of start-ups premature for an exit today. We recommend that investors and entrepreneurs take a rational valuation approach for nanotech start-ups based on competitiveness in their core application areas.”
To build a framework for assessing venture capital investments in nanotechnology, Lux Research analyzed a snapshot of its ongoing, comprehensive database of investments in the field – which contains every institutional VC funding round, IPO, acquisition, and bankruptcy worldwide for companies that are commercializing nanoscale structures with size-dependent properties. The report finds that:
Based on deals completed through September, we estimate that VC investments in nanotech start-ups will reach $650 million in 2006.
The average deal to date in 2006 comes to $11.5 million, 19% higher than 2005’s $9.6 million.
In 2006 through September, 121 different institutional venture capitalists invested in nanotech start-ups, the majority of which had previously invested in the field. Familiar names, such as Harris and Harris Group (H&H) and Draper Fisher Jurvetson (DFJ), continue to dominate, while new entrants such as Bain Capital joined a number of Fortune 500 corporations in casting votes of confidence for companies employing nanotechnology.
Ten venture-backed nanotech start-ups have managed an IPO of shares, raising an aggregate $417.2 million at their debuts with a total implied valuation of $1.69 billion.
The report provides valuation data on nanotech start-ups which have exited to date and a comparison of exits for nanotech start-ups to exits by venture-backed companies as a whole, worldwide. It is available immediately to clients of Lux Research’s Nanotechnology Strategies advisory service. For information on how to become a client, contact Rob Burns, Vice President of Sales, at (646) 723-0708.
About Lux Research:
Lux Research provides market intelligence and strategic advice on nanotechnology and the physical sciences. We help our clients make better decisions to profit from cutting-edge technologies by tapping into our analysts' unique expertise and unrivaled network. Our clients include top decision makers at large corporations, investment professionals at leading financial institutions, CEOs of the most innovative start-ups, and visionary public policy makers. Visit www.luxresearchinc.com for more information.
Contacts
Lux Research, Inc.
Peter Hebert, 646-723-0702
peter.hebert@luxresearchinc.com
Nanogen Wins CDC Contract to Develop Avian Flu Diagnostic
SAN DIEGO, Dec 04, 2006 (BUSINESS WIRE) --
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic
products, announced today it has been awarded a $4.5 million contract
from the U.S. Centers for Disease Control and Prevention (CDC) to
develop a unique multi-analyte Point-Of-Care (POC) diagnostic assay
for Influenza in support of the US Government's efforts to strengthen
its readiness for a potential influenza pandemic. The goal of the
development is to employ proprietary Nanogen technology in a low cost,
high sensitivity POC immunoassay that simultaneously detects Influenza
Type A, Type B, seasonal flu (H1N1 and H3N2) and avian flu (H5N1) in a
simple to use assay format. This development program is partnered with
HX Diagnostics, Inc., which will commercialize the product upon
approval. The current award of $4.5 million funds the first two phases
of a five-phase development project and, if all five phases are funded
by the CDC, can total approximately $12.5 million over the next two to
three years.
"The success of our bid is a strong endorsement of our
capabilities as a diagnostic company and our expertise in areas like
rapid immunoassay technology," said Howard C. Birndorf, Nanogen's
chairman of the board and CEO. "A rapid test for bird flu could play a
significant role in tracking infections and warding off epidemic
spread of this dangerous virus."
The Nanogen product under development is a third generation high
sensitivity lateral flow test designed to be accurate, highly
portable, and simple to use yet with a cost similar to current
influenza POC tests sold today. The immunoassay technology underlying
the design builds upon that employed in Nanogen's current cardiac
infarction products, which are capable of delivering results at the
point of care in as little as 15 minutes.
The test format is also designed to be readily adapted to detect
new strains of the influenza virus as they emerge. Once
commercialized, health professionals could use this test to diagnose
seasonal influenza and as an "early warning system" to identify
individuals with typical flu symptoms who may harbor a potentially
pandemic subtype, giving public health officials early notice of the
emergence of a new subtype. Also, as it will be in general use for
seasonal flu testing, it would be immediately available to deploy to
rapidly and accurately differentiate people with similar symptoms as
having non-flu, seasonal-flu or pandemic-flu in the event of a
pandemic. Nanogen believes this product will be highly competitive and
will meet all criteria for cost, performance, ease of use, and be
highly deployable with a long shelf life.
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians
and physicians worldwide with improved methods and tools to predict,
diagnose, and ultimately help treat disease. The company's products
include real-time PCR reagents, the NanoChip(R)400 electronic
microarray platform and a line of rapid, point-of-care diagnostic
tests. Nanogen's ten years of pioneering research involving
nanotechnology holds the promise of miniaturization and continues to
be supported for its potential for diagnostic and biodefense
applications. For additional information please visit Nanogen's
website at www.nanogen.com.
About HX Diagnostics, Inc.
Founded in 2006, HX is a diagnostics company based in Menlo Park,
California. HX is focused on the development and commercialization of
infectious disease diagnostics including seasonal and pandemic flu
diagnostics that allow physicians and front line care providers to
make rapid assessments of a patient's health status. HX has
relationships with leading avian flu researchers across the globe and
has a product development collaboration with Nanogen, Inc. where
Nanogen will develop a rapid immuno assay for seasonal and pandemic
flu utilizing their third generation lateral flow technology that HX
will commercialize worldwide. The principle investor of HX is Kleiner
Perkins Caufield & Byers Pandemic and Biodefense Fund. For more
information, visit www.kpcb.com.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results to
differ materially from those set forth in the forward-looking
statements, including whether patents owned or licensed by Nanogen
will be developed into products, whether the patents owned by Nanogen
offer any protection against competitors with competing technologies,
whether products under development can be successfully developed and
commercialized, whether results reported by our customers or partners
can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and
elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with
the Securities and Exchange Commission. There is also no assurance
that all of the phases of the CDC development agreement will be funded
by the Federal government, that the development program will be
successful if fully funded, or that the assay to be developed by
Nanogen will be selected by CDC for use under its auspices if that
development is successful. These forward-looking statements speak only
as of the date hereof. Nanogen disclaims any intent or obligation to
update these forward-looking statements.
SOURCE: Nanogen, Inc.
Nanogen, Inc.
Robert Saltmarsh, Chief Financial Officer, 858-410-4600
or
Suzanne Clancy, Corporate Communications, 858-410-4688
sclancy@nanogen.com
or
Porter Novelli Life Sciences
Kim Richards, Media & Investor Relations, 619-849-5377
krichards@pnlifesciences.com
or
HX Diagnostics, Inc.
Risa Stack, CEO, 650-233-3378
rstack@kpcb.com
Copyright Business Wire 2006
GE? no. NNPP! lol
Nano-Proprietary, Inc. Announces Changes to Management Team and Board of Directors
Monday , December 04, 2006 08:40ET
AUSTIN, TX -- (MARKET WIRE) -- 12/04/06 -- Nano-Proprietary, Inc. (OTCBB: NNPP) today announced that Thomas F. Bijou has replaced R.D. (Dan) Burck as a Board Member and as Chief Executive Officer of the Company, effective December 1, 2006. In addition, Bradford S. Lamb was added to the Company's Board of Directors.
Mr. Bijou began his career at General Electric Company, working in the plastics division and at GE Information Services Company. He left GE in 1982 to form Tigon Corporation with several associates. Tigon was a voicemail outsourcing company that was sold to Ameritech in 1988 at a substantial return, and he remained with the Company until 1991. In 1992, Mr. Bijou became CEO of Advanced Telemarketing Corporation ("ATC"), a subsidiary of publicly traded NRP, Inc. By 1996, ATC was the only subsidiary of NRP. During Mr. Bijou's tenure, the market capitalization of NRP increased from $10 million to almost $400 million.
Since 1997, Tom Bijou has been CEO of BHM Associates, Inc. whose activities include mentoring and funding Technology companies. In connection with these BHM activities, Mr. Bijou served as Chairman of Knowledge Communications, Inc., an early pioneer in the distance learning marketplace and provided seed capital and arranged subsequent investment for Freestone Systems/LightSpeed, a Video Storage and Transmission development and IP licensing company. Both companies were sold with substantial returns to investors.
Mr. Lamb is a long-time investor in Nano-Proprietary, Inc. and is currently President of Columbia Power Technologies, an early stage technology company that is commercializing a new generation of clean renewable energy systems utilizing ocean waves. Before joining Columbia Power, he was President of InteLex Corporation, a publisher of online databases used for academic research. Prior to InteLex, Mr. Lamb spent ten years with GE Medical systems in various capital medical equipment sales and sales management positions, including three years in Hong Kong, where he was responsible for CAT Scanner sales in ten countries including China, India, Korea, and the ASEAN countries.
"We are fortunate that an individual with Tom's background and success in technology and venture capital became available to lead us to the next level of our development," said Marc Eller, Chairman of Nano-Proprietary, Inc. "We are also pleased to add two such qualified individuals to our Board of Directors."
"I have had the privilege to be associated with many successful companies over the course of my career," said Tom Bijou, "but only in Nano-Proprietary have I seen such depth in basic research capability along with substantial progress in protecting and marketing its IP. Building value for Shareholders through developing and licensing IP is never a short term or inexpensive task. However Nano-Proprietary is far down the path and well positioned as actual market applications of its IP develop."
Safe Harbor Statement
This press release contains forward-looking statements that involve risks and uncertainties concerning Nano-Proprietary's business, products, and financial results. Actual results may differ materially from the results predicted. More information about potential risk factors that could affect our business, products, and financial results are included in Nano-Proprietary's annual report on Form 10-K for the fiscal year ended December 31, 2005, and in reports subsequently filed by Nano-Proprietary with the Securities and Exchange Commission ("SEC"). All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval System (EDGAR) at www.sec.gov or from Nano-Proprietary's web site listed below. Nano-Proprietary hereby disclaims any obligation to publicly update the information provided above, including forward-looking statements, to reflect subsequent events or circumstances.
About Nano-Proprietary, Inc.
Nano-Proprietary, Inc. is a holding company consisting of two wholly owned operating subsidiaries. Applied Nanotech Inc. is a premier research and commercialization organization dedicated to developing applications for nanotechnology with an extremely strong position in the fields of electron emission applications from carbon film/nanotubes, sensors, functionalized nanomaterials, and nanoelectronics. Electronic Billboard Technology, Inc. (EBT) has a financial interest in technology related to electronic digitized sign technology. Nano-Proprietary's website is www.nano-proprietary.com.
--------------------------------------------------------------------------------
COMPANY CONTACT:
Doug Baker
Chief Financial Officer
Nano-Proprietary, Inc.
248.391.0612
Email Contact
MEDIA CONTACT:
Michael L. Warden
512.736.9296
Email Contact
Source: Nano-Proprietary, Inc.
Nanotech research holds promise for food industry, say scientists
By Ahmed ElAmin
FoodProductionDaily.com
17/11/2006 - Discoveries in nanotechnology are affecting a range of aspects in the food industry, from food safety to the molecular synthesis of new products and ingredients, according to a survey of current research by scientists.
The four major areas in food production that may benefit from nanotechnology development are microscale and nanoscale processing, product development, and methods and instrumentation design for improved safety and biosecurity, the scientists say in an article published in the current issue of the Journal of Food Science.
"The fact that systems with structural features on the nanoscale have physical, chemical, and biological properties substantially different from their macroscopic counterparts is changing the understanding of biological and physical phenomena in food systems," they say.
Nanotechnology, which deals with controlling matter at near-atomic scales to produce unique or enhanced materials, products and devices, has been touted as the next revolution in many industries, including food manufacturing and packaging. Yet the public's concerns have been raised that nanostructured materials could potentially lead to unforeseen health or environmental hazards.
In the food area fears arise over the unknown consequences of digesting nano-scale particles designed to behave in specific way in the body.
In the article scientists Jochen Weiss, Paul Takhistov, and Julian McClements give an overview of the current state of nanotechnology research in the food industry, providing processors with a heads up of the probable changes that may come their way in the sector.
"Strategies to apply nanoscience to the food industry are quite different from these more traditional applications of nanotechnology," the scientists noted. " Food processing is a multitechnological manufacturing industry involving a wide variety of raw materials, high biosafety requirements, and well-regulated technological processes."
The potential benefits of nanotechnology have been recognized by many industries, and commercial products are already being manufactured, such as in the microelectronics, aerospace, and pharmaceutical industries. Developments in these industries are driven by fundamental and applied research in physics, chemistry, biology, engineering, and materials science.
In contrast, applications of nanotechnology within the food industry are rather limited, the scientists say.
Production of nanoscale structures for use in food science and technology therefore frequently relies on an in-depth understanding of thermodynamically driven self-assembly processes, write the scientists.
They suggest areas of current research that could prove useful for the food sector in the near future include the molecular design of protective surface systems, surface engineering, and various methods of manufacturing, such as electrospinning and nanofiltration.
Other areas where nanotechnology has the potential to impact food and agricultural systems include security, disease-treatment delivery methods, tools for molecular and cellular biology, materials for pathogen detection, and the protection of the environment.
Such examples include the use of nanotechnology for achieving further advancements in the security of manufacturing, processing, and shipping of food products through sensors for pathogen and contaminant detection.
Devices to maintain historical environmental records of a particular product and tracking of individual shipments could also be developed, they suggest.
Other nanotechnology developments are systems to provide the integration of sensing, localization, reporting, and remote control of products, and transportation, and the encapsulation and delivery mechanisms for functional ingredients to their specific site of action.
The influence of the material properties of foods at the nanoscale level on their bioavailability and nutritional value has been highlighted by at least two studies. In addition, other scientists have investigated the relationship between the morphology of food materials and their bulk physicochemical properties.
Such studies include ones on biopolymers in solutions, gels, and films. One study found functional nanostructures can incorporate individual biological molecules, which is useful in the development of biosensors that can use natural sugars or proteins as target-recognition groups.
"In summary, there are a large number of potential applications of nanotechnology within the food industry; however, many of these may be difficult to adopt commercially because they are either too expensive or too impractical to implement on an industrial scale," the scientists concluded.
However a limited number of nanotechnology applications may have commercial potential in the near future. Most likely, the limited application of nanotechnology to the food industry will change as nanofabrication technologies become more cost-effective, they suggest.
Such areas include the development of functional ingredients such as drugs, vitamins, antimicrobials, antioxidants, flavorings, colourants, and preservatives.
Association colloids could be another fertile area for commercialisation. Association colloids include surfactant micelles, vesicles, bilayers, reverse micelles, and liquid crystals — used for many years to encapsulate and deliver polar, nonpolar, or amphiphilic functional ingredients.
Nano-emulsions such as the use of high-pressure valve homogenizers or microfluidizers could be used to incorporate functional food components within the droplets, the interfacial region, or the continuous phase.
"While it is difficult to engineer the interfaces to be completely impermeable to compounds in the bulk phase that may interact with the encapsulated compounds, the rate of permeation can often be significantly reduced, thus increasing the kinetic stability of the bioactives," the scientists stated.
Nanostructured multiple emulsions can be another area of work, used to create delivery systems with novel encapsulation and delivery properties. The most common examples of this are oil-in-water-in-oil and water-in-oil-in-water emulsions.
For example, a nanostructured emulsion would consist of nanometer-sized water droplets or reverse micelles contained within larger oil droplets that are dispersed within an aqueous continuous phase.
Functional food components could be encapsulated within the inner water phase, the oil phase, or the outer water phase, thereby making it possible to develop a single delivery system that contains multiple functional components.
The technology could be used to separate aqueous phase components that might adversely react with each other if they were present in the same aqueous phase. It could also be used to protect and release an aqueous phase component trapped within the inner water droplets to a specific site such as the mouth, stomach, or small intestine, they suggest.
Another area for commercialisation is the use of nanostructured multilayer emulsions. Recent studies show that the use of multilayer emulsions can create novel delivery systems, they stated.
Such systems typically consist of oil droplets at the core surrounded by a shell of nanometer thick layers. The shell is comprised of different polyelectrolytes.
Under certain circumstances, emulsions containing oil droplets surrounded by multilayer interfaces have been found to have better stability against environmental stresses than conventional oil-in-water emulsions with single-layer interfaces, they stated.
The Journal of Food Science is a publication of the Institute of Food Technologists.
MFIC Microfluidizer Video:
http://www.microfluidicscorp.com/microflash.html
From SOTK's October 12, 2006 PR:
>>>According to Dr. Christopher L. Coccio, Sono-Tek's CEO and President, "We are continuing to invest time and money in the creation of new products to meet the needs of both the developed and developing world, and the evolution of the electronics and medical industries where we have a significant presence. We are also working to create new business opportunities for our WideTrack coating systems, extending from glass to textile applications to medical coverings in the past year. In addition, we have recently begun an initiative to develop WideTrack coating opportunities in the food industry, particularly as that industry turns to coating technology that includes nanotechnology to prevent spoilage, improve flavorings, and to reduce costs."
Sono-Tek has also recently announced the opening of our Chinese office, and the creation of a Chinese language website. We continue to see opportunities for growth in both China and other parts of Asia, and our new office will help us serve these markets more effectively.<<<
All this and if you annualize Q2 EPS you get a P/E of only 15 with an $18 Million market cap.
gee. No, NNPP.
whee!
Search of Robert Nicolosi, MFIC collaborator at UMass-Lowell, at MassTechPortal.org:
Search results: 7 matches found Sort by: Title IP Type Organization Inventor Summary
1. Nanoemulsions Encapsulate Anti-Oxidant Synergy Formulation (ASF) for Cancer Therapy
IP Type: Licensable Technology
Organization: University of Massachusetts Lowell
Tech Type: Nanotechnology/NEMS
Inventor: Robert Nicolosi
This invention utilizes nanoemulsions as a mechanism for delivering therapeutic formulations for the treatment of cancer ...
2. Treatment of Cancer with with Chemically Modified SopharoLipids(SL)
IP Type: Licensable Technology
Organization: University of Massachusetts Lowell
Tech Type: Therapeutics-Drugs
Inventor: Robert Nicolosi
Sophoro Lipids (SL) are microbial glycol lipids produced by yeast strain Torulopsis. They have been reported to be biosu ...
3. Recrystallization and reformulation of pharmaceuticals into nanoparticles and nanoemulsions
IP Type: Licensable Technology
Organization: University of Massachusetts Lowell
Tech Type: Nanotechnology/NEMS
Inventor: Robert Nicolosi
A method for decreasing the crystal size of drugs, which necessarily increases the active surface area of the drug, whic ...
4. Formulations of Oxidatively Stable Nanoemulsions of Long Chain Polyunsaturated Fatty Acids
IP Type: Licensable Technology
Organization: University of Massachusetts Lowell
Tech Type: Nanotechnology/NEMS
Inventor: Robert Nicolosi
Polyunsaturated fatty such as omega 3 fatty acids are known for their health benefits. These fatty acids are highly nut ...
5. Corn Fiber Oil: Its Preparation and Use
IP Type: Licensable Technology
Organization: University of Massachusetts Lowell
Tech Type: Nanotechnology/NEMS
Inventor: Robert Nicolosi
This is a patented process for purifying oil extracted from corn fiber; which is a byproduct of the agricultural corn in ...
6. Use of Nanoemulsion delivery system to incorporate and increase efficacy of lipid soluble nutrients in beverages and Fat Free or Low Fat Foods
IP Type: Licensable Technology
Organization: University of Massachusetts Lowell
Tech Type: Nanotechnology/NEMS
Inventor: Robert Nicolosi
This invention provides a new methodology for developing better and more efficient nanoemulsion delivery mechanisms. Thi ...
7. Nanoemulsion Delivery of Botulism Toxin Type A
IP Type: Licensable Technology
Organization: University of Massachusetts Lowell
Tech Type: Nanotechnology/NEMS
Inventor: Robert Nicolosi
Dr. Nicolosi's ground-breaking work renders lipid-soluble compounds to water-soluble compounds into stable emulsions rap ...
NNPP up from here, imo
MFIC's MMR/Microfluidizer link at UMass-Lowell website:
Docket No: UML 05-07
Primary Inventor: Robert Nicolosi
Other Inventors:
Title:
Technology: Nanotechnology/NEMS
Description: A method for decreasing the crystal size of drugs, which necessarily increases the active surface area of the drug, which increases it's effectiveness while reducing unwanted side effects (because less of the drug is administered).
Specifically, most synthesized drug crystals are 1000 nm in diameter. This technique employs an "ultra-turbulent" collision of two or more microfluidic solutions containing reagents, which react to crytallize drugs from one to two orders of magnitude smaller in diameter, yielding a greater surface area to volume ratio.
The method employs the Multiple-Stream Mixer/Reactor and Microfluidizer apparatuses.
Applications: Production methods of drugs for any patented or unpatented drug manufacturers, and for generic drug manufacturers. Particular use in manufacturing drugs that were previously unsoluble in water.
Benefits: The process provides a more efficient manufacturing method. The drugs made by this process exhibit a greater surface area to volume of drugs, due to their decreased crystal size. `The drugs made by this process contribute to health benefits because: less dosage is needed to treat illnesses and fewer side effects result; and the cost to consumers decreases because drugs made with this method become more efficient; and previously non-water soluble drugs can be made to be water soluble.
Contact Person: Paul Wormser
Research Lab: Center for Health and Disease Research
Patent Status: Application in Progress
Industrial Nanotech Announces Negotiations With a Fortune Global 500 Company for Sale of Over One Billion Square Feet of Nansulate Shield Over Five Years
http://biz.yahoo.com/pz/061128/109385.html
I did a search of MicroFluidics using Hoovers.com which covers both public and private companies and came up with 2 hits, one a private company and the other, MFIC:
http://www.hoovers.com/free/search/simple/xmillion/index.xhtml?query_string=MicroFluidics&which=...
The private company, Coventor, Inc., has no subsidiaries or divisions named MicroFluidics but "markets software for designing microfluidics and microelectromechanical systems (MEMS) devices, tiny machines that can power drug pumps within a human body or set off an airbag in a car, among many applications for the micromechanisms."
That leaves MFIC Corp. and "its Microfluidics division, the company makes materials processing equipment used to manufacture processed foods, cosmetics, inks, vaccines and drugs, and photographic films."
I emailed IR about the Blue Pacific Flavors/ice cream connection but am waiting for a response.
MFIC: Taste Nanology - Deal or No Deal?
Technology breakthrough
One imminent development in ice cream is being made possible thanks to an exclusive strategic arrangement between Blue Pacific Flavors and MicroFluidics, wherein a new nanotechnology process in conjunction with a unique flavor enhancer StabilEase can create the ultimate in smoother, creamier ice cream.
The addition of a pilot liquid nano processor in Blue Pacific’s repertoire can increase the pressure upon liquids to levels of 40,000 pounds psi versus the typical homogenizers, which reach 4,000 to 8,000 pounds psi. Together with Blue Pacific’s proprietary stabilizer called Stabilize, the implications for the ice cream segment are manifold.
“By using our new nanotechnology process, we create much smaller protein molecules by breaking apart the protein with the equipment and then creating a matrix within the ice cream system with Stabilize, which provides creamy flavor and protects the dairy proteins from conglomerating,” says Walt Postelwait, vice president and general manager at Blue Pacific Flavors, City of Industry, Calif. “This matrix forces the water molecules to disperse into much smaller droplets evenly throughout the mix, which upon freezing forms smaller ice crystals, resulting in a dramatically creamier product.”
The joint venture between MicroFluidics and Blue Pacific has been termed Taste Nanology, which the team defines as: combining science and taste receptor technology with food ingredients to improve rheological and organoleptic properties in food products.
“The ice cream products that result from the new Taste Nanology process have a smoother texture and creamier mouthfeel,” says Postelwait. “For example, a 6 percent butterfat ice cream mix tastes more like a 14 percent butter fat product when this technology is used, and a superpremium ice cream actually tastes like a custard. The potential for improving consumers’ sensory perception of ice cream is exciting.”
Source: newproductsmag.com
Nanotechnology and the Food Industry
Source: softmachines.org blog
November 25, 2006
The use of nanotechnology in the food industry seems to be creeping up the media agenda at the moment. The Times on Saturday published an extended article by Vivienne Parry in its “Body and Soul” supplement, called Food fight on a tiny scale. As the title indicates, the piece is framed around the idea that we are about to see a rerun of the battles about genetic modification of food in the new context of nano-engineered foodstuffs. Another article appeared in the New York Times a few weeks ago: Risks of engineering a better ice cream.
Actually, apart from the rather overdone references to a potential consumer backlash, both articles are fairly well-informed. The body of Vivienne Parry’s piece, in particular, makes it clear why nanotechnology in food presents a confusingly indistinct and diffuse target. Applications in packaging, for example in improving the resistance of plastic bottles to gas permeation, are already with us and are relatively uncontroversial. Longer ranged visions of “smart packaging” also offer potential consumer benefits, but may have downsides yet to be fully explored. More controversial, potentially, is the question of the addition of nanoscaled ingredients to food itself.
But this issue is very problematic, simply because so much of food is made up of components which are naturally nanoscaled, and much of traditional cooking and food processing consists of manipulating this nanoscale structure. To give just one example, the traditional process of making whey cheeses like ricotta consists of persuading whey proteins like beta-lactoglobulin to form nanoparticles each containing a small number of molecules, and then getting those nanoparticles to aggregate in an open, gel structure, giving the cheese its characteristic mechanical properties. The first example in the NY Times article - controlling the fat particle size in ice cream to get richer feeling low fat ice cream - is best understood as simply an incremental development of conventional food science, which uses the instrumentation and methodology of nanoscience to better understand and control food nanostructure.
There is, perhaps, more apparent ground for concern with food additives that are prepared in a nanoscaled form and directly added to foods. The kinds of molecules we are talking about here are molecules which add colour, flavour and aroma, and increasingly molecules which seem to confer some kind of health benefit. One example of this kind of thing is the substance lycopene, which is available from the chemical firm BASF as a dispersion of particles which are a few hundred nanometers in size. Lycopene is the naturally occurring dye molecule that makes tomatoes red, for which there is increasing evidence of health benefits (hence the unlikely sounding claim that tomato ketchup is good for you). Like many other food component molecules, it is not soluble in water, but it is soluble in fat (as anyone who has cooked an olive oil or butter based tomato sauce will know). Hence, if one wants to add it to a water based product, like a drink, one needs to disperse it very finely for it to be available to be digested.
One can expect, then, more products of this kind, in which a nanoscaled preparation is used to deliver a water or oil soluble ingredient, often of natural origin, which on being swallowed will be processed by the digestive system in the normal way. What about the engineered nanoparticles, that are soluble in neither oil nor water, that have raised toxicity concerns in other contexts? These are typically inorganic materials, like carbon in its fullerene forms, or titanium dioxide, as used in sunscreen, or silica. Some of these inorganic materials are used in the form of micron scale particles as food additives. It is conceivable (though I don’t know of any examples) that nanoscaled versions might be used in food, and that these might fall within a regulatory gap in the current legal framework. I talked about the regulatory implications of this, in the UK, a few months ago in the context of a consultation document issued by the UK’s Food Standards Agency. The most recent research report from the UK government’s Nanotechnology Research Coordination Group reveals that the FSA has commissioned a couple of pieces of research about this, but the FSA informs me that it’s too early to say much about what these projects have found.
I’m guessing that the media interest in this area has arisen largely from some promotional activity from the nanobusiness end of things. The consultancy Cientifica recently released a report, Nanotechnologies in the food industry, and there’s a conference in Amsterdam this week on Nano and Microtechnologies in the
Food and Healthfood Industries.
lol ty doc same to ya hun
Thank you and may you get the tastiest pile at the table!
HAPPY THANKSGIVING doc
movement in this stock just baffles me.
NNPP ty for the info doc
Starting to see some divergances on NNPP. This price assumes that the Canon/Toshiba settlement is only worth $15M from them, which is way wrong. I guess when the gap fills, some people will want to buy it. But the company is at a turning point, imo
NaturalNano 'Spotlighted,' ISE-CCM Index Components Nanogen, Altair, FEI Company Cited in Q3 Nanotech Sector Report as Industry Poised to Affect Whole Economy and Aspects of Our Lives, Says Investrend Analyst Sharifzadeh
Business Wire - November 22, 2006 11:52
NEW YORK, Nov 22, 2006 (BUSINESS WIRE) -- (Investrend Research Syndicate) NaturalNano (OTCBB: NNAN) is "spotlighted," and ISE-CCM Nanotechnology index components such as Nanogen (NASDAQ: NGEN), Altair Nanotech (NASDAQ: ALTI) and FEI Company (NASDAQ: FEIC) are among those cited in the report, which notes that US and other industrial governments consider nanotechnology to be a top national priority.
The full report, including important disclosures, disclaimers and analyst's credentials are available at http://www.investrendresearch.com.
The analyst also stated:
"Because of its multidisciplinary, disruptive, and enabling characteristics, it is argued that nanotechnology will affect all industries across the whole economy and eventually will change all aspects of our lives.
"The U.S. government and governments in other industrial countries consider R&D investments in nanotechnology as a top national priority.
"Commercialization of nanotechnology products has already started. This is evident from the fact that all the component companies of the ISE-CCM nanotechnology index are now generating revenues.
"New ideas, new discoveries, new R&D investments, and new innovations and product developments is something of continual nature in the nanotechnology sector.
"During the third quarter of 2006, many of the ISE-CCM nanotechnology index component companies introduced new innovations and new products.
"In the field of nanomaterials and alternative energy Altair Nanotechnologies Inc. demonstrated significant achievements in the third quarter of 2006. During September 2006, Altair introduced their innovative 'NanoSafe (TM) rechargeable nano-titanate battery'.
"The FEI Company introduced its 'Helios NanoLab(TM) DualBeam' which provides new levels of imaging resolution and contrast in a DualBeam system.
"Nanophase Technologies, announced that eleven new nanoparticle products have been added to Alfa Aesar's distribution for research quantities of Nanophase's nanomaterials.
"Nanogen, Inc. expanded its product portfolio to include MGB Alert(TM) real-time PCR reagents designed to assist laboratories in developing tests that can detect sequences associated with varicella-zoster virus and Bordetella bacteria."
The coverage, commissioned by Cronus Capital Markets (http://www.cronuscapitalmarkets.com), and which provides the Homeland Security Sector index in partnership with International Securities Exchange (NYSE: ISE), will continue to be updated quarterly.
Investrend Research subscribes to the "Standards of Practice for Research Providers" at http://www.firstresearchconsortium.com. Enrollment fees for Spotlight Analytics coverage are $4,000 per quarter and the fees were paid by the companies. Analysts are paid in advance of initial reports by Investrend Research to eliminate pecuniary interest, and neither the analyst nor employees of Investrend Research may own or trade stocks of companies under coverage. Each company is also enrolled for investor monitoring by the Shareholders Research Alliance at http://www.shareholdersresearch.com.
The analyst for the NaturalNano "Spotlight" Report is Oren Meytes, and complete information is available at the company's InvestorPower Page, accessible from http://www.investrend.com/company/list.asp?sPathParam=yes.
Anyone interested in receiving alerts regarding Nanotechnology Sector research should email contact@investrend.com with "NSR" in the subject line.
Forward-Looking Statements: Statements in this news release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results.
Investors are advised to read all disclosures carefully before trading in the equities of any enrolled company.
SOURCE: NaturalNano
Investrend Communications, Inc.
Investrend Research Div.
R. Hempel, 718-896-5060
contact@investrend.com
http://www.investrendresearch.com
or
Cronus Capital Markets.
Michael Soni, CEO, 416-368-3700
query@cronuscapitalmarkets.com
http://www.cronuscapitalmarkets.com
Copyright Business Wire 2006 ********************************************************************** As of Saturday, 11-18-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 10-13-2006 for FEIC @ $22.21. As of Saturday, 11-18-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 03-29-2006 for NGEN @ $3.26. For more information on Comtex SmarTrend® Alert, contact your market data provider or go to www.CSTADirect.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright © 2004-2006 Comtex News Network, Inc. All rights reserved.
Nanotech Spices Up Food Industry
Business & Legal Reports - 11/22/2006
Currently, there are about 150 applications of nanotechnology in the food industry, according to Cientifica, a provider of business and technology nano-services. This fact and many others relating to nanotechnology and food were reported in a new survey sponsored by the Pew Charitable Trusts and the Woodrow Wilson International Center for Scholars.
Nanotechnology is the ability to measure, see, manipulate, and manufacture things usually between 1 and 100 nanometers in diameter. A nanometer is one-billionth of a meter.
With the use of nanomaterials food will be wrapped in smart safety packaging that can detect spoilage or harmful contaminants. Nanotechnology can also be used to adjust the taste and nutrient value of food, block harmful cholesterol from entering the bloodstream, reduce pesticide use, and improve plant and animal breeding.
According to one of its authors, the goal of Nanotechnology in Agriculture and Food Production is to develop an early understanding of "what is on the nano-agrifood horizon."
The benefits of nanotechnology in the food industry will likely be accelerated if critical information is provided as soon as possible. Questions of importance include:
Which nano-engineering food products will appear on the market over the next several years?
What are the potential benefits and risks?
Who will be affected?
How can consumers become engaged early on?
The authors hope the report will provide a starting point for future discussions, particularly those involving the U.S. Department of Agriculture, EPA, and the Food and Drug Administration.
The report is available at http://www.nanotechproject.org/50.
Dreaming of a Nanotech Christmas: What Persuades the Public to Embrace and Buy Nanotechnology?
11/22/2006 12:34:23 AM
Will parents put an iPod Nano or Head Nano Titanium tennis racket under the Christmas tree for their children this year? Will holiday revelers hang a Nano-Infinity stocking on their fireplace mantle for Santa Claus to fill? Just what does compel shoppers to either buy nanotechnology products, or avoid them because of real or imagined risks?
With over 350 manufacturer-identified nanotechnology consumer products available for purchase this gift-giving season (see: http://www.nanotechproject.org/consumerproducts), and with $2.6 trillion in manufactured goods incorporating nanotechnology expected by 2014, there is a lot at stake in how these questions are answered.
The results of the first large-scale empirical study of how consumers consider risks and benefits when deciding whether to purchase or use specific nanotechnology products will appear in the December 2006 issue of the journal Nature Nanotechnology. The article's lead author, Steven C. Currall, University College London and London Business School, and a co-author, Neal Lane, Rice University's Baker Institute for Public Policy and former U.S. Presidential Science Advisor, will report their findings at a program and live webcast on Tuesday, December 5th at 2:00 p.m. in the 5th Floor Conference Room of the Woodrow Wilson International Center for Scholars (http://www.wilsoncenter.org/directions). The Nature Nanotechnology article is embargoed until December 5th at 2 p.m. U.S. Eastern Time.
At this program sponsored by the Wilson Center's Project on Emerging Nanotechnologies, the authors will address whether greater popular awareness and understanding of nanotechnology will whet the public's appetite for the technology and lead to increased support for research, or raise concerns about the potential ill effects of new applications. They will discuss how public perceptions of nanotechnology are being shaped. They also will compare the experience of the emergence of nanotechnology to the experience of other "new" technologies, including nuclear power, genetically modified organisms (GMOs), embryonic stem cell research, and biotechnology.
The study was funded by the National Science Foundation (NSF) through Rice's Center for Biological and Environmental Nanotechnology and NSF's Center for Nanotechnology in Society. Surveys were administered by Zogby International.
Dr. Lane is senior fellow in Science and Technology at Rice University's Baker Institute and the Malcolm Gillis University Professor at Rice. While director of NSF (1993-1998) and assistant to the President for Science & Technology and director of the White House Office of Science and Technology Policy (1998-2001), Lane played a major role in establishing America's National Nanotechnology Initiative -- a federal investment to date of more than $6.5 billion in nanotechnology research and development. He is a leading proponent of greater citizen-scientist dialogue and public science education. Dr. Currall, formerly a professor at Rice, is professor of Enterprise and the Management of Innovation and director of the Management Studies Centre at University College London. He also is visiting professor of entrepreneurship and faculty co-director of the Institute of Technology at London Business School. He is an international authority on the application of behavioral science to workplace and marketplace dynamics.
*** Webcast LIVE at http://www.wilsoncenter.org/nano ***
What: Dreaming of a Nanotech Christmas: What Persuades the Public to Embrace and Buy Nanotechnology?
Who: Steven C. Currall, Professor in the Faculty of Engineering Sciences at University College London, and Visiting Professor at London Business School Neal Lane, former U.S. Presidential Science Advisor, and Senior Fellow in Science and Technology Policy at Rice University's Baker Institute for Public Policy Julia A. Moore, Deputy Director, Project on Emerging Nanotechnologies
When: Tuesday, December 5th, 2006, 2:00 - 3:00 p.m.
Where: Woodrow Wilson International Center for Scholars, 5th Floor Conference Room. Ronald Reagan Building and International Trade Center, 1300 Pennsylvania Avenue, NW, Washington, DC
The Project on Emerging Nanotechnologies was launched in 2005 by the Woodrow Wilson International Center for Scholars and The Pew Charitable Trusts. It is dedicated to helping business, governments, and the public anticipate and manage the possible health and environmental implications of nanotechnology.
Nanotech 2007 Poised to Draw Largest Audience in Its Conference History
Nov 19, 2006
More than 4,000 attendees are expected to attend Nanotech 2007, the nation’s largest technical and trade show.
The Nano Science and Technology Institute (NSTI) is busy creating one of the world’s largest scientific and business programs for its Nanotech 2007 Conference and Trade Show [http://www.nsti.org/ Nanotech2007/]. The conference is taking place in Santa Clara, California at the Santa Clara Convention Center May 20-24, 2007. Nanotech 2007 is celebrating its 10th anniversary as the largest small tech conference in the U.S., and will showcase hundreds of technology presentations, an expanded early stage company showcase and more than 30 symposia covering nano in life sciences, electronics, materials, and more.
Nanotech 2007 is a unique gathering of the scientific and business community working on the development and commercialization of nano and small-scale technology. Nanotech 2007 will include hundreds of technical presentations, a dozen vertical industry symposia, Nanotech Ventures (featuring dozens of pre-vetted early stage venture companies), nano job fair, and Expo Hall featuring more than 250 exhibitors from around the globe.
For the latest program updates, bookmark the Nanotech 2007 page at: http://www.nsti.org/Nanotech2007/.
super one! MFIC has been berry berry good to you!
MFIC at 1.80 and 10 million shares outstanding is an emerging leader in the field of nanotechnology as evidenced by their excellent intellectual property, Fortune 500 client base, international scope of their operations and ever improving balance sheet, income statement and cash flow statement which is hard to find in this sector right now. Inferior nanotech stocks have far worse fundamentals than MFIC yet are trading at market caps well over $100 Million compared to MFIC's paltry market valuation of $18 Million.
The recent stock price action with daily 52 week highs is indicating that a proper valuation for MFIC is in the making as we speak.
Alert Triggered for MFIC Corp
MFIC Reached a New 52 Week High at $1.85
MFIC rose 5.1% to a new 52 week high of $1.85. During the last 52 weeks, MFIC's price has ranged from $1.10 on August 10, 2006 to today's high of $1.85.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |